Researchers observed increased agreement between the SDAI- and CDAI-defined remission and Boolean 2.0 compared with Boolean 1.0, especially for patients with early RA (early RA, 95.9% vs 93.4%; established RA, 98.2% vs 98.0%). In addition, SDAI, CDAI, and Boolean 2.0 similarly predicted radiographic stabilization (nonprogression) of RA and better functional outcomes according to the HAQ after 1 year of treatment.

“Using the Boolean 2.0 criteria classifies more patients as achieving remission and increases the agreement with index-based remission criteria without jeopardizing predictive value for radiographic or functional outcomes,” the study authors said. “This revised Boolean definition and the previously provisionally endorsed index-based criteria were endorsed by ACR and EULAR.”

References:

Studenic P, Aletaha D, de Wit M, et al. American College of Rheumatology/EULAR remission criteria for rheumatoid arthritis: 2022 revision. Arthritis Rheumatol. Published online October 23, 2022. doi:10.1002/art.42347